Patent_application_number,Applicant_name,Year_of_application,Patent_system
EP3262065A1,ATRIUM HEALTH,2018,EPO
EP3263594A1,CIGB,2018,EPO
EP3273244A1,SEIKAGAKU CORPORATION,2018,EPO
EP3283617A1,HARVARD MEDICAL SCHOOL,2018,EPO
EP3285798A2,SALK INSTITUTE FOR BIOLOGICAL STUDIES,2018,EPO
EP3302030A1,BAYER,2018,EPO
EP3302032A1,DSM IP ASSETS BV,2018,EPO
EP3307306A2,MIT,2018,EPO
EP3322798A1,TRANSALGAE LTD,2018,EPO
EP3322803A1,BONUMOSE,2018,EPO
EP3325608A1,UNIVERSITY OF TORONTO,2018,EPO
EP3325627A1,UNIVERSITY LAVAL,2018,EPO
EP3333258A2,NOVOZYMES,2018,EPO
EP3334755A1,CELLIVERY THERAPEUTICS INC [KR],2018,EPO
EP3337815A1,CELLIVERY THERAPEUTICS INC [KR],2018,EPO
EP3341400A1,CELLIVERY THERAPEUTICS INC [KR],2018,EPO
EP3344043A2,SCRIPPS RESEARCH INSTITUTE,2018,EPO
EP3350332A1,ADVAXIS INC [US],2018,EPO
EP3351252A1,LOMA LINDA UNIV [US],2018,EPO
EP3354284A1,KOLON LIFE SCIENCE INC [KR],2018,EPO
EP3354739A1,CORTEVA,2018,EPO
EP3355907A1,SILVER CREEK PHARMACEUTICALS INC [US],2018,EPO
EP3360960A1,RIKEN,2018,EPO
EP3362565A1,SANOFI,2018,EPO
EP3366776A1,CJ CHEILJEDANG CORP,2018,EPO
EP3372682A1,UNIVERSITY NANJING,2018,EPO
EP3375876A1,EVONETIX LTD [GB],2018,EPO
EP3376859A1,PROVIVI INC,2018,EPO
EP3377653A1,PEKIN UNIVERSITY,2018,EPO
EP3378936A1,CLARIANT INT LTD [CH],2018,EPO
EP3383408A1,CSIRO,2018,EPO
EP3392656A1,EUROIMMUN,2018,EPO
EP3399033A1,IDEMITSU KOSAN,2018,EPO
EP3406726A1,EPIPLANTA BIOTECH LTD [CN],2018,EPO
EP3409764A1,PROMEGA CORPORATION,2018,EPO